Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out more about the combination of RAD001 and
sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is
effective for treating neuroendocrine tumors.